Over 500 million people worldwide are infected with one or more different and unrelated
types of human hepatitis virus. Such individuals are at a high risk of developing acute or …

RNA interference (RNAi) is an evolutionally conserved gene silencing mechanism present
in a variety of eukaryotic species. RNAi uses short double-stranded RNA (dsRNA) to trigger …

Hepatitis B virus (HBV) causes acute and chronic hepatitis and hepatocellular carcinoma.
Small interfering RNA (siRNA) and lamivudine have been shown to have anti-HBV effects …

The Hu RNA-binding protein family consists of four members: HuR/A, HuB, HuC and HuD.
HuR expression is widespread. The other three neuron-specific Hu proteins play an …

MicroRNAs (miRNAs) are short sequences of noncoding single-stranded RNAs that exhibit
inhibitory effects on complementary target mRNAs. Recently, it has been discovered that …

Hepatitis B virus infection (HBV) is a significant global health problem. Despite the success
of universal hepatitis B vaccination in many countries, more than 350 million individuals …

Hepatocellular carcinoma (HCC), a major form of primary liver cancer, is one of the leading
causes of cancer related deaths worldwide. Hepatitis B and C infections are major risk …

Activating the RNA interference (RNAi) pathway to achieve silencing of specific genes is one
of the most exciting new developments of molecular biology. A particularly interesting use of …

Current options for the treatment of hepatitis B virus (HBV) infections, a common liver cancer
risk factor, are limited. While RNA interference (RNAi) technologies have been shown to …

Primary liver cancer is the fifth most common malignancy in the world and is a leading cause
of cancer-related mortality. Available treatment for hepatocellular carcinoma (HCC), the …